SIRT7 inhibitor 97491

Cell lines

MES-SA cells

Preparation Method

cells were seeded at a final concentration of 2 x 104 cells/mL and 3 x 103 cells/mL, respectively, in a 96-well plate. SIRT7 inhibitor 97491 was dissolved in DMSO , and the cells were treated with diverse concentrations (0, 1, 5, and 10 mM) of SIRT7 inhibitor 97491. Cell viability and cell proliferation were determined after 24 and 72 h of incubation, respectively.

Reaction Conditions

1, 5, 10 µM; 24, 72h

Applications

SIRT7 inhibitor 97491 lead to more than 50% decrease in cell proliferation at concentrations of 5 and 10 µM.

Animal models

Balb/c nude mice

Preparation Method

MES-SA cells (5 x 106 cells) were injected subcutaneously into the right flank of female nude mice. The mice were treated with doxorubicin (2 mg/kg/day) or SIRT7 inhibitor 97491 (20 mg/kg/day) for 3 weeks, except for weekends (n =5 per group). Doxorubicin was used as a general anticancer chemotherapy agent. After 21 days of treatment, the mice were sacrificed and the tumors were harvested.

Dosage form

20mg/kg/day; i.p.；3 weeks

Applications

SIRT7 inhibitor 97491 exerted a strong anticancer effect, similar to but more specific than doxorubicin, on tumor proliferation in vivo, without causing any side effects.

References:

[1] Ji-Hye Kim, et al. Identification of a Novel SIRT7 Inhibitor as Anticancer Drug Candidate. Biochem Biophys Res Commun. 2019 Jan 8;508(2):451-457.